Agilent (A) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Agilent Technologies (A) reported strong Q3 2025 results, with revenue of $1.74 billion, up 10.1% year-over-year, and EPS of $1.37, both surpassing consensus estimates by 4.6% and 0.74% respectively. Key operational highlights include an 81% year-over-year revenue surge in the Agilent Crosslab Group to $744 million, significantly exceeding analyst projections, though the Life Sciences and Diagnostics segment revenue declined 14.3% but still beat estimates. Despite these positive financial beats, Agilent's stock has underperformed the broader market over the past month, returning -1.3% against the S&P 500's +1.3%.

Analysis

Agilent Technologies (A) delivered a Q3 2025 earnings report with notable top- and bottom-line beats, but with significant divergence in underlying segment performance. Total revenue of $1.74 billion represented a 10.1% year-over-year increase and surpassed consensus estimates by 4.6%, while EPS of $1.37 also exceeded expectations. The primary driver of this outperformance was the Agilent Crosslab Group, which posted a remarkable 81% year-over-year revenue surge to $744 million. Strength was also evident in key end markets, particularly Pharmaceutical (+16.5% YoY) and Chemical and advanced materials (+12.1% YoY). However, this growth masks considerable weakness elsewhere. The Life Sciences and Diagnostics segment, despite beating analyst forecasts, contracted by a significant 14.3% year-over-year. Furthermore, the Environmental and Forensics end market declined by 3%, and revenues from Academia and Government missed analyst estimates. This mixed performance likely contributes to the stock's recent underperformance, with a -1.3% return over the past month against the S&P 500's +1.3% gain, and aligns with its current Zacks Rank #3 (Hold) designation.

Key Decisions for Investors

• Investors should scrutinize the conflicting performance drivers, as the headline earnings beat is heavily dependent on the 81% growth in the Agilent Crosslab Group, which may not be sustainable at such a high rate.
• The significant 14.3% year-over-year revenue decline in the Life Sciences and Diagnostics segment is a major red flag, warranting close monitoring of future reports for signs of stabilization or further deterioration.
• Considering the stock's recent underperformance despite the earnings beat, a hold strategy appears prudent until there is greater clarity on whether strength in the Pharmaceutical and Chemical end markets can consistently offset weakness in other key segments.